Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

AP-1 and colorectal cancer

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

Access this article

+ Tax (if applicable)
Add to Favorites
You must be logged in to use this functionality

image of Inflammopharmacology

Activator protein-1 (AP-1) is a transcription factor that consists of either a Jun–Jun homodimer or a Jun–Fos heterodimer. AP-1 regulates the expression of multiple genes essentialfor cell proliferation, differentiation and apoptosis. Numerous reports suggest that AP-1 plays animportant role in various human diseases. Among them, the roles relating to human cancers havebeen strongly suggested for a long time. In human cancers, colorectal cancer is still a leading causeof morbidity and mortality in the world. Since there are some reports about the role of AP-1 incolorectal cancer response to a number of stimuli, such as cytokines and growth factors, and oncogenictransformation, therapeutic inhibition of AP-1 activity has attracted considerable interest. Here, wedemonstrate the biological properties of AP-1 and its role in colorectal cancer, and discuss a possibilityof an AP-1 inhibitor, an adenovirus dominant-negative mutant of c-Jun, as a therapeutic agent for genetherapy.

Affiliations: 1: Department of Gastroenterology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan; 2: Department of Pharmacology and Molecular Therapeutics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan; 3: Department of Pharmacology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Tools

  • Add to Favorites
  • Printable version
  • Email this page
  • Subscribe to ToC alert
  • Get permissions
  • Recommend to your library

    You must fill out fields marked with: *

    Librarian details
    Your details
    Why are you recommending this title?
    Select reason:
    Inflammopharmacology — Recommend this title to your library
  • Export citations
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation